Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Soo Young Kim, Seok Mo Kim, Jun Won Kim, Ik Jae Lee, Tae Joo Jeon, Hojin Chang, Bup Woo Kim, Yong Sang Lee, Hang Seok Chang, Cheong Soo Park

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging. Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64–839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9–10%. The other 16 patients (88.9%) had tumor volume reductions of 2–69%. Six patients (33.3%) had tumor volume reductions ≥50%. Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted.

Original languageEnglish
Article number599
JournalFrontiers in Endocrinology
Publication statusPublished - 2020 Sept 2

Bibliographical note

Publisher Copyright:
© Copyright © 2020 Kim, Kim, Kim, Lee, Jeon, Chang, Kim, Lee, Chang and Park.

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis'. Together they form a unique fingerprint.

Cite this